FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like <b>Alzheimer Society Of Canada</b> Release: Alzheimer Society Research Program Provides $3.4 Million Boost To Dementia Research September 11, 2017 Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of the IND Applica… November 2, 2017 Arkis Biosciences Expands Clinical Use Of Its New Minimally Invasive Tunneling Guidewire Technology April 19, 2017
<b>Alzheimer Society Of Canada</b> Release: Alzheimer Society Research Program Provides $3.4 Million Boost To Dementia Research September 11, 2017
Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of the IND Applica… November 2, 2017
Arkis Biosciences Expands Clinical Use Of Its New Minimally Invasive Tunneling Guidewire Technology April 19, 2017